Exiqon | GenomeWeb

Exiqon

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.

The company said its offer received acceptances from nearly 95 percent of Exiqon shareholders, and it expects to close the deal by June 28.

Qiagen has again extended the offer period and has reduced the acceptance threshold for share capital and voting rights.

Qiagen will hold a greater than 90 percent stake in Exiqon if members of Exiqon's management convert warrants they hold to shares rather than to cash.

In March, Qiagen announced that it had made a roughly $100 million offer for Exiqon in an effort to expand its presence in the RNA analysis field.

Product revenues were up slightly due to the firm's entry into new markets, while services revenues tumbled due to market fluctuations.

Qiagen has submitted an offer to buy all of Exiqon's shares for DKK18 each, for a total aggregate purchase price of DKK683 million ($103.5 million).

The firm's product revenues grew 29 percent year over year to DKK 24.7 million, and it is launching a new online sales platform next month.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.